Secondary myelodysplastic syndrome/acute myeloid leukemia after autologous transplantation

Published: June 16, 2009
Abstract Views: 335
PDF: 337
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

High-dose chemotherapy followed by autologous bone marrow (BM) or peripheral blood (PB) stem cell transplantation (SCT) are being used with increasing frequency in the treatment of hematopoietic malignancies and solid neoplasms. The improvement in survival after hematopoietic stem cell transplantation has drawn increased attention to late complications in long-term survivors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Laurenti, L., Tarnani, M., Chiusolo, P., La Torre, G., Pagano, L., Zini, G., Garzia, M., Zollino, M., Sorà, F., Leone, G., & Sica, S. (2009). Secondary myelodysplastic syndrome/acute myeloid leukemia after autologous transplantation. Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.609